Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2006 by Taylor & Francis Group, LLC. There is no doubt that the academic, industrial, and government communities are recognizing the enormous potential of human brain functional MRI (fMRI) in clinical pharmacological research and drug development. Most of the major pharmaceutical industries have embraced this new technology either via academic collaborations and/or by establishing the methodology in-house. The hope is that fMRI may allow us to demonstrate a functional effect with a potential drug (enhanced or reduced activation) in specific brain regions, in relatively small numbers of patients (n 1/4 10-12). If this did prove to be feasible it offers the potential to evaluate many more molecules in clinical settings quickly. This is potentially very exciting, because one of the challenges faced by the pharmaceutical industry today is the great diversity of potential targets and even greater number of new chemical entities to evaluate in patients.



Book title

In Vivo MR Techniques in Drug Discovery and Development

Publication Date



221 - 236